S Papapetropoulos
S Papapetropoulos
Consultant, Massachusetts General Hospital, Department of Neurology
Verified email at - Homepage
Cited by
Cited by
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
B Zheng, Z Liao, JJ Locascio, KA Lesniak, SS Roderick, ML Watt, ...
Science translational medicine 2 (52), 52ra73-52ra73, 2010
Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease
DM Maraganore, M De Andrade, A Elbaz, MJ Farrer, JP Ioannidis, ...
Jama 296 (6), 661-670, 2006
Technology in Parkinson's disease: challenges and opportunities
AJ Espay, P Bonato, FB Nahab, W Maetzler, JM Dean, J Klucken, ...
Movement Disorders 31 (9), 1272-1282, 2016
A genomic pathway approach to a complex disease: axon guidance and Parkinson disease
TG Lesnick, S Papapetropoulos, DC Mash, J Ffrench-Mullen, L Shehadeh, ...
PLoS genetics 3 (6), e98, 2007
Psychiatric comorbidities of episodic and chronic migraine
DC Buse, SD Silberstein, AN Manack, S Papapetropoulos, RB Lipton
Journal of neurology 260, 1960-1969, 2013
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease
J Pablo, SA Banack, PA Cox, TE Johnson, S Papapetropoulos, ...
Acta Neurologica Scandinavica 120 (4), 216-225, 2009
Drug repurposing from the perspective of pharmaceutical companies
Y Cha, T Erez, IJ Reynolds, D Kumar, J Ross, G Koytiger, R Kusko, ...
British journal of pharmacology 175 (2), 168-180, 2018
Peripheral nerve damage associated with administration of taxanes in patients with cancer
AA Argyriou, M Koltzenburg, P Polychronopoulos, S Papapetropoulos, ...
Critical reviews in oncology/hematology 66 (3), 218-228, 2008
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial
AA Argyriou, E Chroni, A Koutras, J Ellul, S Papapetropoulos, G Katsoulas, ...
Neurology 64 (1), 26-31, 2005
Lrrk2 and Lewy body disease
OA Ross, M Toft, AJ Whittle, JL Johnson, S Papapetropoulos, DC Mash, ...
Annals of Neurology: Official Journal of the American Neurological …, 2006
Psychotic symptoms in Parkinson’s disease: from description to etiology
S Papapetropoulos, DC Mash
Journal of neurology 252, 753-764, 2005
Melatonin MT1 and MT2 receptor expression in Parkinson's disease.
N Adi, DC Mash, Y Ali, C Singer, L Shehadeh, S Papapetropoulos
Medical science monitor: international medical journal of experimental and …, 2010
A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results
AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, ...
Supportive Care in Cancer 14, 1134-1140, 2006
Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation
AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, ...
Journal of pain and symptom management 32 (3), 237-244, 2006
Descriptive epidemiology of cervical dystonia
G Defazio, J Jankovic, JL Giel, S Papapetropoulos
Tremor and Other Hyperkinetic Movements 3, 2013
Patient diaries as a clinical endpoint in Parkinson's disease clinical trials
S Papapetropoulos
CNS neuroscience & therapeutics 18 (5), 380-387, 2012
Post‐stroke spasticity: Predictors of early development and considerations for therapeutic intervention
J Wissel, M Verrier, DM Simpson, D Charles, P Guinto, ...
PM&R 7 (1), 60-67, 2015
SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease
LA Shehadeh, K Yu, L Wang, A Guevara, C Singer, J Vance, ...
PloS one 5 (2), e9104, 2010
The first frontier: digital biomarkers for neurodegenerative disorders
ER Dorsey, S Papapetropoulos, M Xiong, K Kieburtz
Digital Biomarkers 1 (1), 6-13, 2017
Biomarkers associated with migraine and their potential role in migraine management
P Durham, S Papapetropoulos
Headache: The Journal of Head and Face Pain 53 (8), 1262-1277, 2013
The system can't perform the operation now. Try again later.
Articles 1–20